Investigating ioflupane I123 injection and single photon emission tomography as an imaging biomarker for long-term sequelae following mild traumatic brain injury. (2nd January 2018)

• Record Type: Journal Article
• Authors: Reams, Nicole; Anderson, Julie; Perlman, Reid; Li, Wei; Walters, Shaun; Tideman, Samuel; Wang, Chi; Simon, Kelly; Frigerio, Roberta; Maraganore, Demetrius M.
• Is Part Of: Brain injury. Volume 32:Number 1(2018)
• Page Start: 105
• Page End: 112
• Publication Date: 2018-01-02
• Subjects: Clinical trial -- case-control study -- observational study -- parkinson's disease -- parkinsonism -- SPECT -- brain trauma; Brain damage -- Periodicals; Brain -- Wounds and injuries -- Periodicals; Brain Injuries -- Periodicals; 617.481
• DOI: 10.1080/02699052.2017.1388443
• Languages: English
• ISSNs: 0269-9052

Abstract

ABSTRACT: Objective : To determine whether there were differences in clinical outcomes for ioflupane I 123 injection (DaTscan) and single photon emission tomography consistent with early Parkinson's disease (PD) among individuals with a history of mild traumatic brain injury (mTBI). Methods : We performed a case-control study among patients presenting to the Emergency Room (ER) during 2006–2013 with mTBI (cases, n = 34) or without mTBI (controls, n = 33). We performed clinical and imaging measurements in cases and controls at least 1-year post-presentation to the ER (average three years four months). Results : All DaTscans obtained were qualitatively normal. There were no qualitative DaTscan differences between cases and controls. There was, however, a significant increase in caudate asymmetry in controls versus cases ( p = 0.02), but this finding was no longer significant after correction for multiple comparisons. There was a suggestion of a trend of poorer clinical score test measures among those with mTBI, although the overall mean score difference between cases and controls was not clinically significant. Conclusion : Our small study does not provide support for DaTscan changes suggestive of PD in the one to seven years following mTBI. A trend towards poorer clinical measures was seen but was not clinically relevant in our small sample. Further work in a large population is necessary to support these findings.